There were 529 press releases posted in the last 24 hours and 202,608 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Siren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image